Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
Status:
Recruiting
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
This is a dose-escalation Phase Ib clinical trial in 18 patients with newly diagnosed Stage
I-IV ER+/HER2- breast cancer, with the primary cancer in place. These patients have not
received prior therapy for their breast cancer and intend to undergo surgery after four
cycles of therapy.
This is an open-label study, and investigators and subjects are not blinded to the treatment.
The reason for using an open-label study design is because this is a dose-escalation trial,
and the investigators need to determine the potential toxicity before a decision can be made
to continue the dose escalation procedures.
The assignment of patients will not be randomized, as this is a dose-escalation trial.
Phase:
Phase 1
Details
Lead Sponsor:
Eastchester Center for Cancer Care Hoffman Oncology